Leiomyosarcoma Pipeline Review and Market Analysis 2015

This report provides comprehensive information on the therapeutic development for Leiomyosarcoma, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Leiomyosarcoma and special features on late-stage and discontinued projects.

Complete report on H1, 2015 Pipeline Review of “Leiomyosarcoma” addiction with 23 market data tables and 14 figures, spread across 86 pages is http://www.rnrmarketresearch.com/leiomyosarcoma-pipeline-review-h1-2015-market-report.html . (This is a premium report price at US$2000 for a single user PDF license)

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

Scope

·         The report provides a snapshot of the global therapeutic landscape of Leiomyosarcoma

·         The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities

·         The report reviews key players involved in the therapeutics development for Leiomyosarcoma and enlists all their major and minor projects

·         The report summarizes all the dormant and discontinued pipeline projects

·         A review of the Leiomyosarcoma products under development by companies and universities/research institutes based on information derived from company and industry-specific sources

·         Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages

·         A detailed assessment of monotherapy and combination therapy pipeline projects

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Inquire for discount on this report at http://www.rnrmarketresearch.com/contacts/discount?rname=269597 .

Reasons to Buy:

• Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies
• Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
• Develop strategic initiatives by understanding the focus areas of leading companies
• Identify and understand important and diverse types of therapeutics under development for Leiomyosarcoma
• Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
• Devise corrective measures for pipeline projects by understanding Leiomyosarcoma pipeline depth and focus of Indication therapeutics
• Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

More reports on Diseases & treatment :

Pazopanib – Patent, Extension and Data Exclusivity Expiry Snapshot (51 countries)

Need fast access to comprehensive SPC, data exclusivity, and litigation intelligence that’s simple to access and use? Already used by big pharma, biologics manufacturers and their law firms, Patent, Extension and Data Exclusivity Expiry Snapshot saves you days of research and instantly puts you in-the-know. ! NOW WITH ‘USA VIEW’!

“The most extensive source of patent information available” Product Portfolio Manager – Dr Reddys Laboratories

Complete report is available at http://www.rnrmarketresearch.com/pazopanib-patent-extension-and-data-exclusivity-expiry-snapshot-50-countries-market-report.html .

US, Canada & Australia Prostate Cancer Drug Forecast and Market Analysis to 2022

GlobalData has released its new Country report, “PharmaPoint: Prostate Cancer – US, Canada & Australia Drug Forecast and Market Analysis to 2022″. The recent approvals of second-line metastatic castration-resistant prostate cancer (mCRPC) therapies like J&J’s Zytiga (abiraterone acetate) and Medivation/Astellas’ Xtandi (enzalutamide) will drive strong market growth over the next decade. These safe and orally administered treatments will provide safety and convenience benefits over the current standard of care, chemotherapy with docetaxel, while prolonging the overall survival of patients with mCRPC. The December 12, 2012 FDA approval of Zytiga for the added indication of chemotherapy-naïve mCRPC marks the onset of a new treatment paradigm for the disease, in which chemotherapy is relegated to second-line therapy and beyond. For patients with earlier-stage prostate cancer, androgen deprivation therapy with LHRH agonists and first-generation antiandrogens remains the standard of care for suppressing testosterone levels and temporarily controlling the disease.

Prostate Cancer United States Drug Market Analysis to 2022

US prescribers widely use routine PSA screening to diagnose prostate cancer, as well as a DRE. GlobalData’s primary research shows that the majority of patients treated by urologists and medical oncologists in the US in 2011 were diagnosed or monitored using PSA screening. The diagnosis is confirmed and the cancer is staged following a TRUS-guided multiple-core needle biopsy, and any metastases are diagnosed using a bone scan or Computed Tomography (CT) scan (NCCN, 2012). Most prescribers surveyed intend to decrease their use of routine PSA screening to diagnose prostate cancer in asymptomatic patients in response to the recent USPSTF recommendation against it (see Section 5.2.2). While GlobalData predicts that the use of routine PSA screening will slightly decrease, we still believe that it will be the primary tool used in the diagnosis of prostate cancer over the forecast period, as there are currently no better, cost-effective options available.

Request a Sample Copy of US @ http://www.rnrmarketresearch.com/contacts/request-sample?rname=77506

Prostate Cancer Canada Drug Market Analysis to 2022

In Canada, prostate cancer is diagnosed following an abnormal DRE, elevated PSA levels detected during routine screening, or a patients’ presentation with symptoms that leads to either of these tests. A suspected diagnosis of prostate cancer is confirmed by TRUS-guided multiple core needle biopsies, and bone metastases are detected using a CT scan or bone scan. The uptake of routine PSA screening has been high in Canada, but some Canadian physicians surveyed by GlobalData reported that they plan to decrease their use of routine screening in response to the recent USPSTF recommendation against it (Baade et al., 2009).

Request a Sample Copy of Canada @ http://www.rnrmarketresearch.com/contacts/request-sample?rname=77514

Prostate Cancer Australia Drug Market Analysis to 2022

In Australia, prostate cancer is diagnosed following a patient’s presentation with symptoms, elevated PSA levels as a result of routine screening, or an abnormal DRE. The diagnosis is confirmed after multiple core needle biopsies or TRUS, and bone metastases are detected by CT or bone scan. Routine PSA screening is more commonly used in Australia compared with the 5EU, but less frequently than in the US (Baade et al., 2009).

Request a Sample Copy of Australia @ http://www.rnrmarketresearch.com/contacts/request-sample?rname=77513

Scope

- Overview of RA, including epidemiology, etiology, symptoms, diagnosis, pathology and treatment guidelines as well as an overview on the competitive landscape.
- Detailed information on the key drugs in the US including product description, safety and efficacy profiles as well as a SWOT analysis.
- Sales forecast for the top drugs in the US from 2012 to 2022.
- Analysis of the impact of key events as well the drivers and restraints affecting the US Prostate cancer market.

Reasons to buy

- Understand and capitalize by identifying products that are most likely to ensure a robust return
- Stay ahead of the competition by understanding the changing competitive landscape for Prostate cancer
- Effectively plan your M&A and partnership strategies by identifying drugs with the most promising sales potential
- Make more informed business decisions from insightful and in-depth analysis of Prostate cancer drug performance in the US
- Obtain sales forecast from 2012-2022 in The US